CAMPATH-1 antibodies have a long and successful history in the treatment of leukaemia, autoimmune disease and transplant rejection. The first antibody to undergo "humanisation", CAMPATH-1H, permits treatment with limited patient anti-globulin response. It recognises the CD52 antigen which is a small glycosylphosphatidylinositol(GPI)-anchored protein expressed on lymphocytes and mediates cell depletion. We present the 1.9 A structure of the CAMPATH-1H Fab complexed [corrected] with an analogue of the antigenic determinant of CD52. Analysis of the CAMPATH-1H binding site reveals that in contrast to most antibodies CDR L3 plays a dominant role in antigen binding. Furthermore CDR H3, which is essential for effective antigen recognition in most antibodies, participates in only two main-chain interactions in CAMPATH-1H. The CAMPATH-1H binding site is highly basic; ionic interaction with the enthanolamine phosphate of the CD52 GPI anchor has long been hypothesised to be important in antigen binding. The structure reveals a number of important specific ionic interactions, including Lys53H but not Lys52bH as had previously been suggested. Prolonged treatment with CAMPATH-1H can lead to patient anti-idiotype responses which may be exacerbated by the unusually high number of basic residues in the antibody. This suggests that a strategy where redundant basic residues are replaced with neutral counterparts may be effective in further reducing the immunogenicity of this versatile and widely used antibody.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/jmbi.1999.2750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of De Novo Peptide Sequences with Bottom-Up Tag Convolution.
Proteomes
December 2021
Laboratory of Bioinformatics and Mathematical Biology, Alferov University, 194021 St. Petersburg, Russia.
De novo sequencing is indispensable for the analysis of proteins from organisms with unknown genomes, novel splice variants, and antibodies. However, despite a variety of methods developed to this end, distinguishing between the correct interpretation of a mass spectrum and a number of incorrect alternatives often remains a challenge. Tag convolution is computed for a set of peptide sequence tags of a fixed length k generated from the input tandem mass spectra and can be viewed as a generalization of the well-known spectral convolution.
View Article and Find Full Text PDFA BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.
World J Pharm Pharm Sci
November 2021
Arkansas College of Osteopathic Medicine, Fort Smith, AR, USA.
Article Synopsis
- Monoclonal antibodies (mAbs) are engineered medications increasingly used to target specific receptors for treating a variety of diseases, including autoimmune disorders and cancers.
- The review aims to classify mAbs based on system diseases, providing concise synopses of their pharmacological profiles, mechanisms of action, clinical uses, and side effects.
- It will cover specific mAbs like Abciximab and Bevacizumab for cardiovascular issues, Denosumab for musculoskeletal disorders, and various mAbs for autoimmune diseases and tumors, as well as IL-6 antagonists being explored for COVID-19 treatment.
Highly sensitive cytokine release assay incorporating high-density preculture.
J Immunotoxicol
December 2021
Transrational Research, Daiichi Sankyo RD Novare Co, Ltd, Edogawa-ku, Tokyo, Japan.
Immunostimulatory effects of monoclonal antibodies (mAb) through binding to F receptors (FR) on immune cells are a likely cause of cytokine release syndrome. However, it is difficult to detect the potential risk of FR-dependent cytokine release associated with mAb in the current standard cytokine release assays (CRA), including the air-drying solid-phase method using human peripheral blood mononuclear cells (PBMC). To increase the sensitivity to detect FR-dependent cytokine release due to mAb, a high-density preculture (HDC) method was incorporated into the air-drying solid-phase CRA.
View Article and Find Full Text PDFAbrogating biologics interference in flow cytometric crossmatching.
Hum Immunol
August 2021
Histocompatibility Laboratory, McLendon Clinical Laboratories, UNC Hospitals, Chapel Hill, NC, USA; Department of Pathology & Laboratory Medicine, UNC School of Medicine, Chapel Hill, NC, USA. Electronic address:
The flow cytometric crossmatch is currently the gold standard for evaluating donor and recipient histocompatibility. The assay however does have limitations and is sensitive to false positive reactions resulting from the presence of non-HLA antibodies or therapy related immune biologics. Such false positive reactions can lead to the inappropriate decline of an acceptable donor organ or unnecessary therapeutic intervention.
View Article and Find Full Text PDFDe Novo Sequencing of Peptides from Top-Down Tandem Mass Spectra.
J Proteome Res
November 2015
Center for Algorithmic Biotechnology, Institute of Translational Biomedicine, Saint Petersburg State University , 7-9 Universitetskaya nab., Saint Petersburg 199034, Russia.
De novo sequencing of proteins and peptides is one of the most important problems in mass spectrometry-driven proteomics. A variety of methods have been developed to accomplish this task from a set of bottom-up tandem (MS/MS) mass spectra. However, a more recently emerged top-down technology, now gaining more and more popularity, opens new perspectives for protein analysis and characterization, implying a need for efficient algorithms to process this kind of MS/MS data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!